SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-007810
Filing Date
2022-05-09
Accepted
2022-05-09 16:06:42
Documents
69
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20220331x10q.htm   iXBRL 10-Q 1179727
2 EX-31.1 adap-20220331xex31d1.htm EX-31.1 9819
3 EX-31.2 adap-20220331xex31d2.htm EX-31.2 10562
4 EX-32.1 adap-20220331xex32d1.htm EX-32.1 6129
5 EX-32.2 adap-20220331xex32d2.htm EX-32.2 6111
  Complete submission text file 0001558370-22-007810.txt   5240200

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20220331.xsd EX-101.SCH 42437
7 EX-101.CAL adap-20220331_cal.xml EX-101.CAL 46674
8 EX-101.DEF adap-20220331_def.xml EX-101.DEF 151390
9 EX-101.LAB adap-20220331_lab.xml EX-101.LAB 332828
10 EX-101.PRE adap-20220331_pre.xml EX-101.PRE 260967
63 EXTRACTED XBRL INSTANCE DOCUMENT adap-20220331x10q_htm.xml XML 907072
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 22904896
SIC: 2836 Biological Products, (No Diagnostic Substances)